Hansa Medical AB to Present at the Evercore ISI HealthConX Conference
Lund, Sweden, November 21, 2018 - Hansa Medical AB (PR Newswire) (Nasdaq Stockholm:HMED) (“Hansa Medical” or the “Company”), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that Søren Tulstrup, President and CEO of Hansa Medical, will present at the Evercore ISI HealthConX Conference at the Boston Harbor Hotel on Tuesday, November 27, 2018 at 10:35am ET.
A live webcast will be available on the Investors section under Event & Webcasts of the Company's website: http://hansamedical.com/en/investors-media/events/. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About Hansa Medical
Hansa Medical (NASDAQ Stockholm:HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.
For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations
Hansa Medical AB (Publ)
Mobile: +46 70 717 5477
Swedish Investor and Media Relations:
+46 70-311 99 60
U.K. Investor and Media Relations:
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000
U.S. Investor and Media Relations:
Stephanie Marks / David Rosen (media)
+1 212 600 1902